MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Stopped early · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Key facts

Study ID

NCT05090566

Run by

Pfizer

People needed

46

Starts

2021-10-27

Expected to finish

2026-03-11

Last updated by the study team

2026-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
• Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
• Measurable disease defined by at least one of the following:
• Serum M-protein >/= 0.5 g/dL by SPEP
• Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
• Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
• ECOG performance status 0 -1
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1

You may not qualify if…

• Active plasma cell leukemia
• Amyloidosis
• Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
• POEMS syndrome
• Any active uncontrolled bacterial, fungal, or viral infection
• Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
• Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
• Sub-Study A Only: Previous treatment with BCMA bispecific antibody
• Sub-Study B Only: Previous treatment with BCMA directed therapy

Where it is running

• Banner Gateway Medical Center — Gilbert, Arizona, United States
• Banner Gateway Medical Pavilion — Gilbert, Arizona, United States
• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
• Banner Health d.b.a. Banner MD Anderson Cancer Center — Phoenix, Arizona, United States
• Beverly Hills Cancer Center — Beverly Hills, California, United States
• Clinical Research Advisors — Encino, California, United States
• Clinical Research Advisors — Los Angeles, California, United States
• Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD — Los Angeles, California, United States
• Cedars Sinai Medical Center — Los Angeles, California, United States
• Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI) — Los Angeles, California, United States
• Clinical Research Advisors — Los Angeles, California, United States
• Cedars-Sinai Tarzana — Tarzana, California, United States
• Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida, United States
• University of Miami — Coral Gables, Florida, United States
• Sylvester Comprehensive Cancer Center- Deerfield Beach — Deerfield Beach, Florida, United States
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• UHealth Tower — Miami, Florida, United States
• The Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
• OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility) — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada
• The Ottawa Hospital - General Campus — Ottawa, Ontario, Canada
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.